Goldman Sachs
HQL

Goldman Sachs’s abrdn Life Sciences Investors HQL Stock Holding History

Goldman Sachs’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-19,365
Closed -$290K – 5324
2020
Q1 		$290K Buy
+19,365
New +$317K ﹤0.01% 4527

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MC
Matisse Capital Portland, Oregon $234M AUM 19.72% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Cohen & Steers
Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return

Goldman Sachs's HQL Position: Q2 2020 in Review

Goldman Sachs sold out of abrdn Life Sciences Investors (HQL) in Q2 2020, closing a stake of 19,365 shares — an estimated $290K sold.

Goldman Sachs first reported a position in HQL in Q1 2020 and held it in 1 quarter. The position peaked at $290K in Q1 2020. 70 funds tracked by Wall St. Rank hold HQL as of Q2 2020.

  • Goldman Sachs reported no remaining abrdn Life Sciences Investors position as of Q2 2020 after selling out during the quarter.
  • Goldman Sachs sold 19,365 abrdn Life Sciences Investors shares in Q2 2020, an estimated $290K.
  • Goldman Sachs first reported a position in abrdn Life Sciences Investors in Q1 2020 and held it in 1 quarter.
  • Goldman Sachs's abrdn Life Sciences Investors position peaked at $290K in Q1 2020.
  • 70 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2020.

Based on Goldman Sachs's 13F filing for Q2 2020, filed 12 Aug 2020.